Live Quote · NASDAQARVNHealthcare· Biotechnology

Arvinas, Inc.

$8.39 2.32%(+$0.19)
TickerSpark Score
56/100
Mixed
70
Valuation
40
Profitability
60
Growth
80
Health
30
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARVN research report →

52-Week Range28% of range
Low
$6.06
Current
$8.39
High
$14.51
Company Overviewwww.arvinas.com

About the company

Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates.

CEO
Randy Teel
IPO
2018
Employees
430
HQ
New Haven, CT, US

Price Chart

+6.20% · this period
$13.83$10.04$6.24Jul 02Dec 31Jul 02
Valuation
Market Cap
$541.33M
P/E
-2.43
P/S
6.06
P/B
1.39
EV/EBITDA
-2.14
Div Yield
0.00%
Profitability
Gross Margin
97.43%
Op Margin
-279.31%
Net Margin
-247.54%
ROE
-44.39%
ROIC
-46.80%
Growth & Income
Revenue
$262.60M · -0.30%
Net Income
$-80,800,000 · 59.38%
EPS
$-1.28 · 53.79%
Op Income
$-114,900,000
FCF YoY
-5.59%
Performance & Tape
52W High
$14.51
52W Low
$6.06
50D MA
$8.82
200D MA
$10.68
Beta
1.75
Avg Volume
846.81K

Get TickerSpark's AI analysis on ARVN

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Jun 24, 26Smaldone Alsup Laurieother15,527
Jun 24, 26Smaldone Alsup Laurieother22,714
Jun 24, 26Norwalk Leslie Vother15,527
Jun 24, 26Norwalk Leslie Vother22,714
Jun 24, 26Morrison Briggsother15,527
Jun 24, 26Morrison Briggsother22,714
Jun 24, 26Kennedy Edward Moore Jr.other15,527
Jun 24, 26Kennedy Edward Moore Jr.other22,714
Jun 24, 26Cunningham Everettother15,527
Jun 24, 26Cunningham Everettother22,714
Coverage · ARVN

Our ARVN coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on ARVN yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate ARVN report →
Internal Compare

Similar companies

Peers in the same neighborhood.